{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:59:18Z","timestamp":1771880358211,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.esmoop.2025.105515","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T16:59:19Z","timestamp":1753289959000},"page":"105515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["CDX2 expression as a predictive and prognostic biomarker of 5-FU response in cancer of unknown primary"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7837-8359","authenticated-orcid":false,"given":"H.E.","family":"Fuentes Bayne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-5022","authenticated-orcid":false,"given":"R.","family":"Suleiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1281-0364","authenticated-orcid":false,"given":"R.A.","family":"Eiring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0664-9447","authenticated-orcid":false,"given":"P.W.","family":"McGarrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-6199","authenticated-orcid":false,"given":"S.D.","family":"Thome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8686-4867","authenticated-orcid":false,"given":"R.P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2025.105515_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nrc3646","article-title":"Cancer of unknown primary site: still an entity, a biological mystery and a metastatic model","volume":"14","author":"Greco","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2025.105515_bib2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canep.2019.06.006","article-title":"The currently declining incidence of cancer of unknown primary","volume":"61","author":"Rassy","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105515_bib3","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/annonc\/mdr536","article-title":"Survival in cancer of unknown primary site: population-based analysis by site and histology","volume":"23","author":"Hemminki","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105515_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/cancers10040108","article-title":"Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site","volume":"10","author":"Selves","year":"2018","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105515_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PAP.0000000000000256","article-title":"An algorithmic immunohistochemical approach to define tumor type and assign site of origin","volume":"27","author":"Bellizzi","year":"2020","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105515_bib6","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/gast.2000.18142","article-title":"CDX1 and CDX2 expression during intestinal development","volume":"119","author":"Silberg","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.esmoop.2025.105515_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102643","article-title":"The prognostic potential of CDX2 in colorectal cancer: harmonizing biology and clinical practice","volume":"121","author":"Badia-Ramentol","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105515_bib8","first-page":"3296","article-title":"Expression and significance of homeodomain protein CDX2 in gastric carcinoma and precancerous lesions","volume":"18","author":"Qin","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105515_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00000478-200303000-00003","article-title":"CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas","volume":"27","author":"Werling","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105515_bib10","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/modpathol.3800698","article-title":"Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7","volume":"19","author":"Vang","year":"2006","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105515_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0210-4806(04)73048-X","article-title":"Expresi\u00f3n de CDX2 en lesiones de vejiga urinaria y uretra","volume":"28","author":"Ortiz-Rey","year":"2004","journal-title":"Actas Urol Esp"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105515_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/PAI.0000000000000250","article-title":"CDX-2 expression in primary lung adenocarcinoma","volume":"24","author":"Cowan","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105515_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4240\/wjgs.v3.i11.159","article-title":"CDX2 as a marker for intestinal differentiation: its utility and limitations","volume":"3","author":"Saad","year":"2011","journal-title":"World J Gastrointest Surg"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105515_bib14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(08)70151-7","article-title":"Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions","volume":"9","author":"Varadhachary","year":"2008","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105515_bib15","first-page":"546","article-title":"Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy","volume":"100","author":"Sato","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105515_bib16","article-title":"Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience","author":"Fuentes","year":"2024","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105515_bib17","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.6004\/jnccn.2011.0117","article-title":"NCCN clinical practice guidelines occult primary","volume":"9","author":"Ettinger","year":"2011","journal-title":"J Natl Compr Canc Net"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105515_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kr\u00e4mer","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105515_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02543-1","article-title":"Real-world data analysis of patients with cancer of unknown primary","volume":"11","author":"Kang","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105515_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4236\/jct.2012.31005","article-title":"Carcinoma of unknown primary site: outcomes in patients with a colorectal molecular profile treated with site specific chemotherapy","volume":"3","author":"Greco","year":"2012","journal-title":"J Cancer Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105515_bib21","first-page":"112","article-title":"A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile","volume":"11","author":"Hainsworth","year":"2012","journal-title":"Clin Colorectal Canc"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105515_bib22","first-page":"162","article-title":"Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary","volume":"32","author":"Schuette","year":"2009","journal-title":"Onkologie"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105515_bib23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/1097-0142(20010201)91:3<592::AID-CNCR1039>3.0.CO;2-5","article-title":"A randomized phase II trial in patients with carcinoma of an unknown primary site","volume":"91","author":"Dowell","year":"2001","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105515_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/path.4897","article-title":"Thymidylate synthase is functionally associated with ZEB1 and contributes to the epithelial-to-mesenchymal transition of cancer cells","volume":"242","author":"Siddiqui","year":"2017","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105515_bib25","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Salonga","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105515_bib26","doi-asserted-by":"crossref","first-page":"986","DOI":"10.4161\/cbt.7.7.6181","article-title":"Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?","volume":"7","author":"Showalter","year":"2008","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105515_bib27","first-page":"261","article-title":"The role of Reg IV in colorectal cancer, as a potential therapeutic target","volume":"19","author":"Hu","year":"2015","journal-title":"Contemp Oncol (Pozn)"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105515_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/j.gastro.2005.10.001","article-title":"Reg IV activates the epidermal growth factor receptor\/Akt\/AP-1 signaling pathway in colon adenocarcinomas","volume":"130","author":"Bishnupuri","year":"2006","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105515_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047545","article-title":"Reg IV is a direct target of intestinal transcriptional factor CDX2 in gastric cancer","volume":"7","author":"Naito","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2025.105515_bib30","article-title":"The clinical significance and mechanisms of REG4 in human cancers","volume":"10","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105515_bib31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.21873\/cgp.20151","article-title":"Regulation of REG4 expression and prediction of 5-fluorouracil sensitivity by CDX2 in ovarian mucinous carcinoma","volume":"16","author":"Koh","year":"2019","journal-title":"Cancer Genomics Proteomics"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105515_bib32","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1158\/0008-5472.CAN-09-4701","article-title":"CDX2 regulates multidrug resistance 1 gene expression in malignant intestinal epithelium","volume":"70","author":"Takakura","year":"2010","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105515_bib33","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1349-7006.2007.00538.x","article-title":"Mechanism of multidrug recognition by MDR1\/ABCB1","volume":"98","author":"Yasuhisa","year":"2007","journal-title":"Cancer Sci"},{"issue":"47","key":"10.1016\/j.esmoop.2025.105515_bib34","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2025.105515_bib35","series-title":"CDX2 as a Predictive Biomarker of Drug Response in Colon Cancer","author":"Raab","year":"2021"},{"issue":"10452","key":"10.1016\/j.esmoop.2025.105515_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study","volume":"404","author":"Kr\u00e4mer","year":"2024","journal-title":"Lancet"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925013845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925013845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:13:36Z","timestamp":1759612416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925013845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2059702925013845"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105515","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CDX2 expression as a predictive and prognostic biomarker of 5-FU response in cancer of unknown primary","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105515"}}